Pharmacoeconomic evaluation of olaparib monotherapy in patients with newly diagnosed advanced BRCA mutation epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer

CHEN Binbin, FAN Changsheng

PDF(6538 KB)
主办：上海医药工业研究院
　　　中国药学会
ISSN 1672-9188   CN 31-1939/R   SLYHAA
World Clinical Drug
PDF(6538 KB)
World Clinical Drug ›› 2021, Vol. 42 ›› Issue (06) : 501-508. DOI: 10.13683/j.wph.2021.06.014
Article

Pharmacoeconomic evaluation of olaparib monotherapy in patients with newly diagnosed advanced BRCA mutation epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer

    {{javascript:window.custom_author_en_index=0;}}
  • {{article.zuoZhe_EN}}
Author information +
History +

HeighLight

{{article.keyPoints_en}}

Abstract

{{article.zhaiyao_en}}

Key words

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations
{{article.zuoZheEn_L}}. {{article.title_en}}. {{journal.qiKanMingCheng_EN}}. 2021, 42(06): 501-508 https://doi.org/10.13683/j.wph.2021.06.014

References

Publishing order | Descend order by publishing year | Descend order by cited within

References

{{article.reference}}

Funding

RIGHTS & PERMISSIONS

{{article.copyrightStatement_en}}
{{article.copyrightLicense_en}}
PDF(6538 KB)

Accesses

Citation

Detail
Sections
Recommended

/

〈 〉